The abstract, as provided, opens with a familiar problem: regulatory approval in high-stakes fields such as drug development demands statistical evidence from large-scale randomized controlled trials. The authors then note the high financial cost of such trials, but the text cuts off mid-sentence, leaving the proposed solution unspecified.

Based on the title, "Optimizing Social Utility in Sequential Experiments," the paper appears to treat trial design as a trade-off between evidence quality and cost, with sequential experimentation as the suggested framework. However, because the abstract is incomplete, no concrete methods, results, or policy implications can be accurately summarized from this source alone.

Readers interested in the full approach will need to consult the complete paper on arXiv. This digest can only report the stated motivation and the apparent direction implied by the title.